Online citations, reference lists, and bibliographies.
← Back to Search

Predictive And Prognostic Factors For The Outcome Of The Patients Receiving Pegylated Liposomal Doxorubicin For Advanced Breast Cancer

S. Khallaf, Jasmine Roshdy, Abeer Ibrahim
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Purpose: The treatment of advanced breast cancer (ABC) is still challenging aiming mainly to improve or maintain the quality of life. The efficacy of pegylated liposomal doxorubicin (PLD) was proven in patients with ABC. Because its expensive treatment there is a great need to find the predictive factors for the clinical outcome of PLD. Our purpose was to evaluate the factors which would affect the clinical outcomes in patients receiving PLD for advanced breast cancer. Methods: Retrospectively, we studied the medical records of 60 eligible patients during the period of seven years (Jan. 2011-Dec. 2017). All patients were treated in Medical Oncology Department, South Egypt Cancer Institute, Assiut University, Egypt. We included only patients with visceral metastasis who received at least 2 cycles of PLD and had radiological assessment after that. Clinical benefit rate of PLD and survival outcome were assessed and correlated with patients and disease characteristic. Results: The majority of patients had a performance status grade II (81.7%), recurrent disease (86.7%), more than one metastatic site (83.3%), and chemoresistance to previous anthracycline (75%). The clinical benefit rate (CBR) to PDL was 30%. We found statistical significant association between higher CBR and biological subtypes (p  0.001), type of metastatic breast disease (p = 0.003), chemosensitivity to anthracycline (p  0.001), and the number of previous lines of chemotherapy (p = 0.041). The median progression-free survival (PFS) was five months. There was a statistically-significant improvement of PFS among patients with anthracycline-sensitive tumors compared to those with anthracycline-resistant tumors (10 months vs. 5 months, respectively, p = 0.004). The most common toxicity was palmar-plantar erythrodysesthesia (28% for all grade and 9% for grade 3 or more). There was no severe cardiotoxicity or treatment-related death. Conclusion: Pegylated liposomal doxorubicin appears to be more effective in patients with (luminal B with Her2neu positive, triple-negative and in her2neu amplified), also we noticed that de novo metastatic disease, patient who are not heavily pretreated tumors and patients with the anthracycline-sensitive tumor get more benefit from PLD than others.
This paper references
10.1093/ANNONC/MDL477
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).
D. Lorusso (2007)
10.1093/annonc/mdn728
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
P. Barrett-Lee (2009)
10.1038/sj.bjc.6603158
The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial
S. Al-Batran (2006)
10.1634/THEONCOLOGIST.8-SUPPL_2-3
Liposomal anthracyclines in metastatic breast cancer: clinical update.
E. Rivera (2003)
10.4103/GMIT.GMIT_8_17
Pegylated Liposomal Doxorubicin-induced Palmar-plantar Erythrodysesthesia
Joana Moreira-Barros (2018)
10.1200/JCO.1997.15.10.3185
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.
M. Ranson (1997)
Chemotherapy and Biotherapy: Guidelines and Recommendations for Practice
K. Brown (2001)
2019) SEER Explorer. Breast Cancer-Stage Distribution of SEER Incidence Cases, 2007-2016 by Sex
N. Howlader (2016)
10.1007/s10549-016-4033-3
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study
N. Harbeck (2016)
10.1016/S1734-1140(09)70018-0
Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.
T. Šimůnek (2009)
10.1186/1471-2407-11-373
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
M. Fiegl (2011)
SEER Explorer. Breast Cancer-Stage Distribution of SEER Incidence Cases
N Howlader (2007)
10.1186/1471-2407-10-2
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
J. Huober (2009)
10.1200/JCO.2004.08.157
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Alan M. Keller (2004)
10.1016/J.EJCA.2005.12.011
A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).
R. Coleman (2006)
10.1007/s10557-016-6711-0
Anthracycline Chemotherapy and Cardiotoxicity
John Mcgowan (2016)
10.1634/THEONCOLOGIST.10-90003-20
Extending survival with chemotherapy in metastatic breast cancer.
J. O'Shaughnessy (2005)
10.1016/j.jgo.2013.07.004
Bi-weekly liposomal doxorubicin for advanced breast cancer in elderly women (≥ 70 years).
U. Basso (2013)
Chemotherapy and biotherapy guidelines and recommendations for practice
Martha Polovich (2005)
10.1159/000080363
Phase II Study of Single-Agent Pegylated Liposomal Doxorubicin HCl (PLD) in Metastatic Breast Cancer After First-Line Treatment Failure
B. Mlineritsch (2004)
10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z
Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
O. Lyass (2000)
10.4155/CLI.15.8
Clinical trial end points relevant to patients and society for rare cancers
S. Khakoo (2015)
10.3390/cancers7020815
Effects of Age on the Detection and Management of Breast Cancer
Andrew McGuire (2015)
10.1054/bjoc.1999.0958
A unified definition of clinical anthracycline resistance breast cancer
X. Pivot (2000)
10.1007/s10549-005-0143-z
Optimizing the treatment of metastatic breast cancer
J. Gralow (2005)
10.1093/ANNONC/MDI078
Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?
A. Fabi (2005)
10.1371/journal.pone.0133569
Efficacy and Cardiotoxicity of Liposomal Doxorubicin-Based Chemotherapy in Advanced Breast Cancer: A Meta-Analysis of Ten Randomized Controlled Trials
Meiyuan Xing (2015)
IBM SPSS Statistics for Windows
Ibm Corp (2013)
Panelmembers-Personalizing the Treatment of Women with Early Breast Cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer
A. Goldhirsch (2013)



Semantic Scholar Logo Some data provided by SemanticScholar